{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:59:26Z","timestamp":1794610766776,"version":"4.9.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Lobular breast cancer often shows only low [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake, limiting the sensitivity to detect metastases. Alternative tracers, targeting tumor activated fibroblasts or estrogen receptors, can offer higher accuracy. Also, Somatostatin Receptor 2 (SSTR2) is significantly expressed in some breast cancers, particularly in estrogen receptor rich tumors. Typical pulmonary carcinoids also have low [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG accumulation, but approximately 63% of well-differentiated lesions express SSTR2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report the case of a 66-year-old female patient with lobular breast cancer and a coincidentally discovered typical carcinoid of the lung. On subsequent [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTATATE PET\/CT to stage the carcinoid tumor, two SSTR2 positive focal lesions in the bones were present, without [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake but with mild sclerosis, atypical for metastasis of carcinoids. Biopsy confirmed osseous breast cancer metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SSTR2 expression in normal breast tissue and breast carcinoma has been described previously. However, the case underscores the importance of awareness of atypical presentations of cancer within a multi-tracer approach, whereby receptor profile and morphology must be carefully integrated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01462-4","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:53:18Z","timestamp":1781175198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidental [68Ga]Ga-DOTATATE uptake in bone metastases of breast carcinoma in a patient with a secondary carcinoid tumor"],"prefix":"10.1186","volume":"16","author":[{"given":"Jan","family":"Kemle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0130-7542","authenticated-orcid":false,"given":"Sabin G.","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-2258","authenticated-orcid":false,"given":"Alexander","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilly","family":"Nothhelfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-7267","authenticated-orcid":false,"given":"Gad","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-0281","authenticated-orcid":false,"given":"Cornelia","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-8692","authenticated-orcid":false,"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"10","key":"1462_CR1","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.21873\/anticanres.11129","volume":"36","author":"T Fujii","year":"2016","unstructured":"Fujii T, Yajima R, Kurozumi S, et al. Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma. Anticancer Res. 2016;36(10):5481\u20135. https:\/\/doi.org\/10.21873\/anticanres.11129.","journal-title":"Anticancer Res"},{"issue":"5","key":"1462_CR2","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.radcr.2026.02.003","volume":"21","author":"E Varshney","year":"2026","unstructured":"Varshney E, Syed A, Gupta A, Prasath S, Sp H. Occult breast carcinoma presenting as isolated vertebral metastasis with negative PET-CT but detected on contrast-enhanced MRI: A case report. Radiol Case Rep. 2026;21(5):2263\u20137. https:\/\/doi.org\/10.1016\/j.radcr.2026.02.003.","journal-title":"Radiol Case Rep"},{"key":"1462_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000002133","author":"M Lenaerts","year":"2026","unstructured":"Lenaerts M, van der Voort L, Smidt ML, et al. The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [18F] fluorodeoxyglucose PET. Nucl Med Commun. 2026. https:\/\/doi.org\/10.1097\/MNM.0000000000002133.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"1462_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/RLU.0000000000004760","volume":"48","author":"YT Huang","year":"2023","unstructured":"Huang YT, Chen TW, Chen LY, Huang YY, Lu YS. The Application of 18 F-FES PET in Clinical Cancer Care: A Systematic Review. Clin Nucl Med. 2023;48(9):785\u201395. https:\/\/doi.org\/10.1097\/RLU.0000000000004760.","journal-title":"Clin Nucl Med"},{"key":"1462_CR5","doi-asserted-by":"publisher","first-page":"1358070","DOI":"10.3389\/fonc.2024.1358070","volume":"14","author":"T Li","year":"2024","unstructured":"Li T, Zhang J, Yan Y, Tan M, Chen Y. Applications of FAPI PET\/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review. Front Oncol. 2024;14:1358070. https:\/\/doi.org\/10.3389\/fonc.2024.1358070.","journal-title":"Front Oncol"},{"issue":"1","key":"1462_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41181-017-0023-y","volume":"2","author":"I Dude","year":"2017","unstructured":"Dude I, Zhang Z, Rousseau J, et al. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography. EJNMMI Radiopharm Chem. 2017;2(1):4. https:\/\/doi.org\/10.1186\/s41181-017-0023-y.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"10","key":"1462_CR7","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2967\/jnumed.116.189035","volume":"58","author":"SU Dalm","year":"2017","unstructured":"Dalm SU, Haeck J, Doeswijk GN, de Blois E, de Jong M, van Deurzen CHM. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists? J Nucl Med. 2017;58(10):1609\u201314. https:\/\/doi.org\/10.2967\/jnumed.116.189035.","journal-title":"J Nucl Med"},{"issue":"6","key":"1462_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.nucmedbio.2008.04.010","volume":"35","author":"F Wang","year":"2008","unstructured":"Wang F, Wang Z, Wu J, et al. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR. Nucl Med Biol. 2008;35(6):665\u201371. https:\/\/doi.org\/10.1016\/j.nucmedbio.2008.04.010.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"1462_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-025-07651-4","volume":"211","author":"KR Chandekar","year":"2025","unstructured":"Chandekar KR, Satapathy S, Dharmashaktu Y, et al. Somatostatin receptor-targeted theranostics in patients with estrogen receptor-positive metastatic breast cancer-a prospective exploratory study. Breast Cancer Res Treat. 2025;211(2):363\u201373. https:\/\/doi.org\/10.1007\/s10549-025-07651-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1462_CR10","doi-asserted-by":"publisher","first-page":"e233408","DOI":"10.1148\/radiol.233408","volume":"312","author":"GA Ulaner","year":"2024","unstructured":"Ulaner GA, VanderMolen LA, Li G, Ferreira D. Dotatate PET\/CT and (225)Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer. Radiology. 2024;312(1):e233408. https:\/\/doi.org\/10.1148\/radiol.233408.","journal-title":"Radiology"},{"issue":"12","key":"1462_CR11","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1007\/s00259-022-05848-z","volume":"49","author":"V Rufini","year":"2022","unstructured":"Rufini V, Lorusso M, Inzani F, et al. Correlation of somatostatin receptor PET\/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study. Eur J Nucl Med Mol Imaging. 2022;49(12):4182\u201393. https:\/\/doi.org\/10.1007\/s00259-022-05848-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1462_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/1817-1737.140134","volume":"9","author":"E Tatci","year":"2014","unstructured":"Tatci E, Ozmen O, Gokcek A, et al. 18F-FDG PET\/CT rarely provides additional information other than primary tumor detection in patients with pulmonary carcinoid tumors. Ann Thorac Med. 2014;9(4):227\u201331. https:\/\/doi.org\/10.4103\/1817-1737.140134.","journal-title":"Ann Thorac Med"},{"key":"1462_CR13","doi-asserted-by":"publisher","unstructured":"Petrella F, Cara A, Cassina EM, et al. Pulmonary Carcinoids: Diagnostic and Therapeutic Approach. Cancers (Basel). 2025;17(17). https:\/\/doi.org\/10.3390\/cancers17172748.","DOI":"10.3390\/cancers17172748"},{"issue":"5","key":"1462_CR14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2214\/AJR.10.5954","volume":"197","author":"QC Meisinger","year":"2011","unstructured":"Meisinger QC, Klein JS, Butnor KJ, Gentchos G, Leavitt BJ. CT features of peripheral pulmonary carcinoid tumors. AJR Am J Roentgenol. 2011;197(5):1073\u201380. https:\/\/doi.org\/10.2214\/AJR.10.5954.","journal-title":"AJR Am J Roentgenol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01462-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:02:15Z","timestamp":1787054535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01462-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01462-4","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient gave written consent for the publication of this case report. Ethics approval is not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient gave written consent for the publication of this case report.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest or competing interests for this work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"129"}}